Ketamine Therapy
The Anaesthetic That Learned to Treat Depression
A drug used to sedate soldiers in Vietnam is now being infused into people with treatment-resistant depression — and it works within hours, not weeks.
The Idea
Most antidepressants work, when they work, by gradually adjusting serotonin levels over weeks. Ketamine does something stranger and faster. It blocks NMDA receptors — the brain's main receivers for glutamate, its most abundant excitatory neurotransmitter — and in doing so, it appears to trigger a rapid surge of synaptic plasticity. In plain terms: it seems to temporarily make the brain more malleable, more capable of forming new connections. Neurons that had gone quiet start talking again. The technical term is synaptogenesis — the sprouting of new synaptic links — and in animal studies, ketamine seems to reverse the synaptic loss associated with chronic stress and depression remarkably quickly. What makes this clinically striking is the timeline. Where SSRIs require weeks of consistent use before mood lifts, ketamine patients often report significant relief within hours of an infusion. For someone who has cycled through multiple antidepressants without improvement — a population estimated at roughly a third of people with major depression — that speed is not a minor detail. It is the difference between enduring and not enduring. The FDA approved esketamine (a nasal spray formulation, brand name Spravato) in 2019 for treatment-resistant depression — the first genuinely new mechanism of action approved for depression in decades. But the science is still catching up to the clinical reality. Researchers don't fully understand why the relief often fades after days or weeks, or why some people respond and others don't. What is clear is that ketamine has cracked open a conversation about how depression works that was, until recently, surprisingly closed.
In the World
In 2006, Carlos Zarate, a psychiatrist at the National Institute of Mental Health in Bethesda, published a small but quietly seismic study. He gave seventeen patients with treatment-resistant depression a single intravenous infusion of ketamine. Within two hours, many showed dramatic reductions in depressive symptoms. Within a day, 71 percent of them met the criteria for a significant antidepressant response. This was not a gradual improvement — it was a before-and-after picture taken within a single afternoon. Zarate's patients weren't experiencing a mild dip in mood. Many had tried multiple medications over years. Some had been through electroconvulsive therapy. The standard tools had failed them, and they had largely been told to keep trying variations of the same approaches. What Zarate's results suggested — and what subsequent trials reinforced — was that something entirely different was happening in the brain during a ketamine infusion. Not just a boost in serotonin, but a kind of structural reset. Since then, ketamine clinics have opened across the US, Europe, and Australia, operating in a complicated space between psychiatric medicine and wellness culture. Some are run by rigorous clinical teams pairing infusions with psychotherapy — the emerging field of ketamine-assisted psychotherapy — on the theory that the window of plasticity the drug opens is also a window for doing meaningful psychological work. Others operate with less integration. The treatment's legitimacy is real; the regulation is still catching up.
Why It Matters
Even if ketamine therapy is not something you would ever pursue yourself, understanding it reframes something important about how we think about depression. For decades, the dominant public mental model has been the chemical imbalance story — too little serotonin, fix it with a pill. That story was always an oversimplification, but it had cultural staying power. Ketamine's mechanism doesn't fit it at all, and that's clarifying. It points toward a model of depression that involves the physical structure of the brain — the density and responsiveness of its connections — not just its chemical bath. Depression, on this view, is partly a problem of rigidity: a brain stuck in well-worn grooves of negative prediction, unable to update. Plasticity, then, becomes a form of relief. That reframe has implications beyond treatment. It suggests that anything which meaningfully increases neural plasticity — certain kinds of therapy, sleep, exercise, even profound experiences — might have depressive symptoms as a target, not just mood in general. Ketamine is the bluntest and fastest version of this idea. But the idea itself is worth sitting with: that the depressed brain may not be chemically broken so much as structurally frozen.
A Question to Ponder
If the brain can be made more malleable — more open to new patterns — what would you want to do with that window?
Get a new one of these every morning.
Start learning with Thinkable